Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. is a cannabis company that cultivates, manufactures, distributes and sells medical and adult-use cannabis products through vertically integrated operations. Its portfolio includes flower, pre-rolls, vaporizer cartridges, edibles, concentrates, topicals, tinctures and beverages sold under brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, JAMS and Anthem. The company operates U.S. retail and wholesale businesses alongside an international medical-cannabis platform serving Europe and other overseas markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueFlower, pre-rolls, vaporizer cartridges and medical inhalation products.
Edibles, beverages and other ingestible cannabis products.
Cannabis concentrates, oils and related extraction-based products.
Topical and liquid cannabis products for medical and adult-use consumers.
Wholesale product distribution and asset-light brand licensing arrangements.
Products
Reported · share of revenue- Retail72.8 %
- Wholesale Revenue26.2 %
- Management Fee Income1.0 %
Source: 40-F FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Curaleaf sells to adult-use consumers and medical cannabis patients through its own U.S. retail stores and other licensed dispensaries. Wholesale partners purchase branded products for resale across licensed retail networks, while international medical products reach patients through clinics, pharmacies and telemedicine platforms. Healthcare professionals, hospital pharmacies and medical-cannabis distributors are important channels for the company’s European operations, including standardized preparations in Spain.
Purchase flower, vapes, edibles and other branded products through Curaleaf stores and licensed dispensaries.
Buy regulated cannabis products for therapeutic use through state-licensed retail channels.
Purchase Curaleaf brands for resale, expanding distribution beyond company-operated retail stores.
Clinics, pharmacies and telemedicine platforms distribute Curaleaf medical products to patients.
Support access to standardized cannabis preparations in emerging regulated medical markets.
Strategy
Curaleaf’s strategy combines brand building, customer-focused product assortment and operational control across cultivation, manufacturing, retail and distribution. The company is expanding wholesale relationships, asset-light licensing and international medical-cannabis channels to increase market access without relying exclusively on owned retail infrastructure. Its European platform emphasizes regulated medical products, scientific research and specialized technologies such as the QMID inhalation device.
Distinctive brands and broad price points can improve consumer retention and retail shelf access.
Wholesale relationships increase product reach across licensed dispensaries beyond owned stores.
European medical markets provide an avenue for regulated cross-border growth and specialized products.
Brand licensing and third-party distribution can broaden reach while moderating capital requirements.
Geography
The United States is Curaleaf’s core operating market, with company-owned cultivation, manufacturing and retail infrastructure. The company reported second-quarter 2026 international revenue of $51 million against total revenue of $340 million, implying an estimated 15% international contribution, while U.S. operations represented approximately 85%. Curaleaf International distributes through European clinics, pharmacies and telemedicine platforms and also maintains distribution links across Canada and Australasia.
Risks
Curaleaf operates in a heavily regulated industry where U.S. federal cannabis restrictions, state licensing requirements and evolving international rules can limit market access and financial services. Its TSX listing imposes additional constraints on investments and fund transfers involving U.S. cannabis operations, while exchange and clearing restrictions could affect shareholder liquidity. Competition from illicit operators, other multistate operators, adjacent consumer categories and licensed international producers can pressure pricing, brand share and utilization of the company’s vertically integrated assets.
- U.S. federal and state regulatory uncertaintyImpact: CriticalLikelihood: High
Changes in enforcement, licensing or cannabis classification can restrict operations, investment and market access.
Exposure - Limited financial-services accessImpact: HighLikelihood: High
Cannabis-related banking and financing restrictions can constrain liquidity, borrowing and growth investment.
Exposure: U.S. operations and external financing
- TSX listing compliance constraintsImpact: HighLikelihood: Low
TSX requirements limit certain investments and fund transfers involving U.S. cannabis activities; noncompliance could threaten listing status.
Exposure - Illicit-market competitionImpact: High
Unlicensed sellers avoid regulatory, compliance and tax burdens, enabling lower prices and potentially reducing legal-market demand.
Exposure: U.S. adult-use and medical markets
- Intensifying legal-market competitionImpact: Medium
Multistate operators, small producers, cannabinoid companies and adjacent consumer categories compete on price, quality and distribution.
Exposure: U.S. and international product markets
Accounting
Judgemental itemsRetail and wholesale sales have different pricing and cost structures, so changes in channel mix affect reported revenue, gross profit and comparability.
Impact: Revenue and gross margin volatility
Cultivated and manufactured cannabis inventory requires costing and potential write-down judgments when products become obsolete or selling prices weaken.
Impact: Cost of goods sold, inventory and gross profit
The scope of Section 280E and the 2026 rescheduling framework remains uncertain across medical and adult-use activities.
Impact: Income tax expense, deferred taxes and operating cash flow
Acquired brands, licenses and operating assets depend on forecasts for regulated markets, pricing and future cash generation.
Impact: Operating income and asset carrying values
Retail stores, cultivation facilities and controlled subsidiaries require judgments about lease obligations and entities included in consolidated statements.
Impact: Assets, liabilities, depreciation and operating expenses
Similar listed companies
Publicly listed companies with a comparable business focus.
Trulieve Cannabis Corp.
TRLV · Medicinal Chemicals & Botanical Products
Verano Holdings Corp.
VRNO · Agricultural Production-Crops
Marimed Inc.
MRMD · Medicinal Chemicals & Botanical Products
Cannabist Co Holdings Inc.
Agricultural Production-Crops
Cannabist Co Holdings Inc., formerly Columbia Care, is a U.S.
Ascend Wellness Holdings, Inc.
AAWH · Medicinal Chemicals & Botanical Products
cbdMD, Inc.
YCBD · Perfumes, Cosmetics & Other Toilet Preparations
Last updated: 24/09/2026